title: Doxorubicin-induced ovarian toxicity.
abstract: BACKGROUND
  Young cancer patients may occasionally face infertility and premature gonadal failure. Apart from its direct effect on follicles and oocytes, chemotherapy may induce ovarian toxicity via an impact on the entire ovary. The role of doxorubicin in potential ovarian failure remains obscure. Our intention was to elucidate doxorubicin-related toxicity within ovaries.
  
  
  METHODS
  Female mice were injected intraperitoneally with 7.5 or 10 mg/kg doxorubicin and their ovaries were visualized in vivo by high resolution MRI, one day and one month following treatment. Ovaries of other treated mice were excised and weighed at the same post-treatment intervals. Ovarian histological sections were stained for TUNEL or active caspase-3 and follicles were counted and categorized. Ovulation rates were evaluated in superovulated female mice treated with doxorubicin.
  
  
  RESULTS
  A single injection of doxorubicin resulted in a major reduction in both ovarian size and weight that lasted even one month post treatment. A dramatic reduction in ovulation rate was observed one week after treatment, followed by a partial recovery at one month. Histological examination revealed positive staining of TUNEL and active caspase-3. We observed a significant reduction in the population of secondary and primordial follicles one month following treatment.
  
  
  CONCLUSIONS
  Our results may imply a mechanism of chemotherapy-induced ovarian toxicity, manifested by reduced ovulation and accompanied by a reduction in ovarian size, caused probably by an acute insult to the ovary.
authors.affiliation: Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.
authors.forename: Irit
authors.initials: I
authors.lastname: Ben-Aharon
authors.forename: Hadas
authors.initials: H
authors.lastname: Bar-Joseph
authors.forename: Galia
authors.initials: G
authors.lastname: Tzarfaty
authors.forename: Lital
authors.initials: L
authors.lastname: Kuchinsky
authors.forename: Shulamith
authors.initials: S
authors.lastname: Rizel
authors.forename: Salomon M
authors.initials: SM
authors.lastname: Stemmer
authors.forename: Ruth
authors.initials: R
authors.lastname: Shalgi
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002452:Cell Count; D003603:Cytotoxins / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D009929:Organ Size / Q000187:drug effects; D010049:Ovarian Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D010053:Ovary / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology
chemical_list: D000903:Antibiotics, Antineoplastic; D003603:Cytotoxins; D004317:Doxorubicin